<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040429</url>
  </required_header>
  <id_info>
    <org_study_id>NorCAPITAL.02</org_study_id>
    <nct_id>NCT01040429</nct_id>
  </id_info>
  <brief_title>The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial</brief_title>
  <acronym>NorCAPITAL</acronym>
  <official_title>The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study IS to

        -  explore the underlying pathophysiology of chronic fatigue syndrome (CFS) in adolescents,
           particularly focusing on genetics, infections/immunology, endocrinology, autonomic
           control and cognitions

        -  to assess the effect of clonidine (a drug that attenuates sympathetic nervous activity)
           in adolescent CFS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean steps/day count during one week</measure>
    <time_frame>8 weeks after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue scores</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Algometer testing response</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic symptom scores</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life-score</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability scores</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>School attendance</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean steps/day count during one week</measure>
    <time_frame>30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on cognitive function tests</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean arterial pressure (MAP) during head-up tilt-test</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in heart rate during head-up tilt-test</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in LF/HF-ratio (a measure of autonomic control) during head-up tilt-test</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal levels (inluding tryptophan metabolites)</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological analyses</measure>
    <time_frame>8 and 30 weeks after inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Chronic Fatigue Syndrome</condition>
  <condition>Myalgic Encephalomyelitis</condition>
  <arm_group>
    <arm_group_label>Clonidine capsula</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose capsula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients &lt; 35 kg; 50 microgram (2 capsula) x 2/day for patients &gt; 35 kg.
Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients &lt; 35 kg; 25 microgram (2 capsula) x 2/day for patients &gt; 35 kg.</description>
    <arm_group_label>Clonidine capsula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose capsula</intervention_name>
    <description>Day 1-56 (week 1-8): 1 capsula x 2/day for patients &lt; 35 kg; 2 capsula x 2/day for patients &gt; 35 kg.
Day 57-63 (week 9): 1 capsula x 1/day for patients &lt; 35 kg; 1 capsula x 2/day for patients &gt; 35 kg</description>
    <arm_group_label>Lactose capsula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persisting or constantly relapsing fatigue lasting 3 months or more.

          -  Functional disability resulting from fatigue to a degree that prevent normal school
             attendance

        Exclusion Criteria:

          -  Another disease process or current demanding life event that might explain the fatigue

          -  Another chronic disease (in particular pheochromocytoma, polyneuropathy, Renal
             insufficiency)

          -  Permanent use of pharmaceuticals (including hormone drugs)

          -  Permanently bed-ridden

          -  Positive pregnancy test

          -  Evidence of reduced cerebral and/or peripheral circulation due to vessel disease

          -  Know hypersensitivity towards clonidine or inert substances (lactose, sakkarose) in
             capsula

          -  Abnormal ECG (in particular bradyarrythmias due to sick sinus syndrome or AV-block.
             Isolated ectopic beats do not lead to exclusion)

          -  Supine heart rate &lt; 50 beats/min

          -  Supine systolic blood pressure &lt; 85 mmHg

          -  Systolic blood pressure fall upon standing &gt; 30 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vegard Bruun Wyller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Pediatrics, Oslo University Hospital, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Pediatrics, Oslo University Hospital Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>PO box 4950 Nydalen, 0424 Oslo</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Wyller VB, Eriksen HR, Malterud K. Can sustained arousal explain the Chronic Fatigue Syndrome? Behav Brain Funct. 2009 Feb 23;5:10. doi: 10.1186/1744-9081-5-10.</citation>
    <PMID>19236717</PMID>
  </reference>
  <reference>
    <citation>Wyller VB, Due R, Saul JP, Amlie JP, Thaulow E. Usefulness of an abnormal cardiovascular response during low-grade head-up tilt-test for discriminating adolescents with chronic fatigue from healthy controls. Am J Cardiol. 2007 Apr 1;99(7):997-1001. Epub 2007 Feb 16.</citation>
    <PMID>17398200</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2009</study_first_submitted>
  <study_first_submitted_qc>December 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2009</study_first_posted>
  <last_update_submitted>November 19, 2012</last_update_submitted>
  <last_update_submitted_qc>November 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Vegard Bruun Wyller</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>Clonidine</keyword>
  <keyword>Autonomic nervous system</keyword>
  <keyword>Stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Encephalomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

